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Oncolytic virotherapy is safe and clinically active in solid
tumors, however its efficacy in hematologic malignancies
as well as in combination with checkpoint inhibitors and
radiation is unexplored. To simulate advanced lymphoma,
A20 cells were injected subcutaneously on bilateral flanks
of BALB/c mice and treatment initiated on day 17 to only
the right flank tumor with local irradiation (Irr), intratu-
moral (i.t.) vaccinia virus (VACV) and i.t. anti-CTLA-4
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mAb (Irr-VACV-CTLA4, Figure 1). The Irr-VACV-
CTLA4 regimen was the most effective in eradicating or
shrinking both treated and untreated tumors and extend-
ing survival, followed by the Irr-VACV regimen. Treat-
ment with Irr-VACV-CTLA4, led to initially a mature,
activated NK cell (KLRG1+CD27+) infiltrate (day 6 post-
treatment) followed by a CD8+T cells infiltrate (day+13) in
treated tumors. In contrast, treatment with VACV-
CTLA4 led to activated NK cell accumulation (day +6) fol-
lowed by a CD8+ T cell infiltrate (day+13) in non-treated
tumors. Importantly, CD8+CD44hi T cells isolated from
the blood and spleens of the treated mice showed func-
tional specificity to A20 lymphoma cells, but not to MHC-
matched tumor cells (CT26) in intra-cellular stains for
IFN-g. Splenocyte-derived A20-specific CD8+CD44hi
T cells were induced most efficiently in the Irr-VACV-
CTLA4 regimen-treated mice, while blood-derived A20-
specific CD8+CD44hi T cells were induced most efficiently
in the Irr-VACV regimen-treated mice. Viral plaque assays
(VPA) showed lack of live viral particles in both treated
and untreated tumors upon sacrificing mice 4 to 10 weeks
after treatment initiation. Surprisingly, VPA assays identi-
fied live virus in the livers of Irr-VACV-CTLA4 regimen-
treated mice, which paralleled a reduced metastatic load.
Our findings are the first to demonstrate the potential of
combination immunotherapy with oncolytic viruses and
checkpoint inhibitors in hematologic malignancies. The
antitumor activity is attributed to the induction of an
effective and specific immune response. This finding is
corroborated by the significant infiltration with mature
activated NK cells, followed by CD8+ T cells, in both trea-
ted and untreated tumors. Importantly, the tumor-specific
CD8+ T cells showing a memory phenotype (CD44hi) sug-
gest the effective induction of a potent immune memory
response. Effective targeting of distant metastases after
intratumoral administration is also an important finding
with significant clinical implications. This novel combina-
tion immunotherapy with oncolytic viruses and check-
point inhibitors following local tumor irradiation is now
being translated to a Phase I proof-of-concept clinical trial
in non-Hodgkin’s lymphoma at our institution.
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